22. The immunoconjugate of any one of claims 19 to 21 wherein the cytotoxic agent is selected from MMAE and MMAF.

23. The immunoconjugate of any one of claims 19 to 22 wherein the cytotoxic agent is covalently bound to said antigen binding protein.

24. The immunoconjugate of any one of claims 20 to 23 wherein said linker is a cleavable linker.

25. The ~~immunogojugat~~ immunoconjugate of any one of claims 20 to 23 wherein said linker is a non-cleavable linker.

26. The immunoconjugate of any one of claims 20 to 25 wherein the linker is selected from 6-maleimidocaproyl (MC), maleimidopropanoyl (MP), valine-citrulline (val-cit), alanine-phenylalanine (ala-phe), p-aminobenzyloxycarbonyl (PAB), N-Succinimidyl 4-(2-pyridylthio)pentanoate (SPP), N-succinimidyl 4-(N-maleimidomethyl)cyclohexane-1 carboxylate (SMCC), and N-Succinimidyl (4-iodo-acetyl) aminobenzoate (SIAB).

27. The immunoconjugate of any one of claims 19 to 26 wherein said immnuoconjugate is engulfed by a tumor cell when contacted with a tumor cell.

28. A pharmaceutical composition comprising an antigen binding protein or immunoconjugate according to any preceding claim and a pharmaceutically acceptable carrier.

29. ~~A method of~~ Use of the composition of claim 28 in the manufacture of a medicament for treating a human patient afflicted with an inflammatory disorder or disease ~~which method comprises the step of administering the composition of claim 28~~.

30. Use of the composition of claim 27 in the manufacture of a medicament for treating a human patient afflicted with a B cell lymphoma such as Multiple myeloma (MM) or Chronic Lymphocytic Leukaemia (CLL).

31. An antigen binding protein or immunoconjugate according to any one of claims 1 to 27 for use in treating a human patient afflicted with a B cell lymphoma such as Multiple Myeloma (MM) or Chronic Lymphocytic Leukaemia (CLL).